Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15503164 | 0.87 | HTR2C (0.47) | PNMTHTR2C | |
| Bromide SCHEMBL2310713 | 0.85 | HTR2C (0.46) | PNMTHTR2C | |
| SCHEMBL16038281 | 0.81 | CD44 (0.47) | CD44PNMTMAOBADRA2AADRA2B | |
| Bromide SCHEMBL16037813 | 0.79 | CD44 (0.46) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL22993478 | 0.78 | HTR2A (0.50) | CD44PNMTHTR2CADRA2AADRA2B | |
| SCHEMBL23683891 | 0.78 | PNMT (0.46) | CD44PNMTMAOBHTR2CADRA2A | |
| SCHEMBL24747204 | 0.78 | HTR2C (0.47) | CD44PNMTMAOBHTR2CADRA2A | |
| SCHEMBL23022301 | 0.78 | PNMT (0.53) | CD44PNMTHTR2CADRA2AADRA2B | |
| SCHEMBL16038610 | 0.78 | HTR2C (0.45) | CD44PNMTMAOBHTR2CADRA2A | |
| Bromide SCHEMBL17583891 | 0.76 | PNMT (0.44) | CD44PNMTMAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3172202-B1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INT (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-2892891-B1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-07 | — | — | US | disclosed |
| US-RE46886-E1 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-RE46886-E1 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2225233-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | Glaxo Group Limited (GB) | 2010-09-08 | — | — | EP | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | S1PR3, S1PR1, S1PR2 | CD44 4451/4885PNMT 2885/4885MAOB 2216/4885 |
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | CD44 3384/4885PNMT 3390/4885MAOB 290/4885 |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, TPH2, HTR1B | CD44 4812/4885PNMT 66/4885MAOB 11/4885 |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | S1PR3, S1PR1, S1PR2 | CD44 4449/4885PNMT 2928/4885MAOB 2241/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | CD44 3384/4885PNMT 3390/4885MAOB 290/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | CD44 3384/4885PNMT 3390/4885MAOB 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.